Microchip Biotech announced that the clinical trial application for injectable NW001 developed by the company in cooperation with Chengdu Microchip Xinyu Biotechnology Co., Ltd. to treat advanced malignant tumors was recently accepted by the Drug Evaluation Center of the State Drug Administration. The acceptance number is CXSL2600833. The acceptance date is August 5, 2026.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.